Companies /Consumer Cyclical

Tesla Inc

NASDAQ: TSLA Auto Manufacturers
$347.86
▼ $6.95 (−1.96%) today
Markets open · 12:23pm ET

Q2 2025 Earnings

Reported Jul 23, 2025, 4:14pm ET · SEC source
$0.40
Miss −1.11%
EPS · est. $0.40
$22.5B
Beat +1.67%
Revenue · est. $22.1B
+12.3%
Beating market
TSLA vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
−8%−4%0Jul 23Jul 24report 4:14pm ETearnings+0.1%−9.1%
−8%−4%0Jul 23Jul 24earnings+0.1%−9.1%
TSLA −9.1%S&P 500 +0.1%
−8%−4%0Jul 23Jul 24report 4:14pm ETearnings+0.0%−9.1%
−8%−4%0Jul 23Jul 24earnings+0.0%−9.1%
TSLA −9.1%NASDAQ +0.0%
−9%−6%−3%0Jul 22Jul 31report 4:14pm ETearnings−0.6%−7.6%
−9%−6%−3%0Jul 22Jul 31earnings−0.6%−7.6%
TSLA −7.6%S&P 500 −0.6%
−8%−4%0Jul 22Jul 31report 4:14pm ETearnings−0.4%−7.6%
−8%−4%0Jul 22Jul 31earnings−0.4%−7.6%
TSLA −7.6%NASDAQ −0.4%
−8.20%
Day of report
+3.52%
Next session
+0.97%
One week
+13.53%
30 days

S&P 500 over the same 30 days: +1.27%.

Did TSLA Beat Earnings? Q2 2025 Results

Tesla delivered a mixed second quarter, narrowly missing earnings expectations while edging ahead on revenue as deepening margin pressure underscored the cost of its aggressive push into autonomy and AI. Non-GAAP EPS came in at $0.40, falling just short of the $0.40 consensus by 1.11%, while revenue of $22.50 billion edged past estimates by 1.67%, though it still represented an 11.8% decline year over year. The primary drag was a steep contraction in automotive revenue, which fell 16% to $16.66 billion, compounded by a sharp drop in regulatory credit sales to $439 million from $890 million a year ago and lower vehicle average selling prices. GAAP operating income tumbled 42% to $923 million, with R&D expense surging to $1.59 billion as the company expanded its AI compute infrastructure and launched its Robotaxi service in Austin. The results arrive as broader auto sector peers also navigate tariff headwinds, adding another layer of demand uncertainty. Looking ahead, Tesla said it has sufficient liquidity to fund its roadmap, with a more affordable model and Cybercab volume production both targeted for 2026.

Key Takeaways
  • Decline in vehicle deliveries drove lower automotive revenue
  • Lower regulatory credit revenue reduced both revenue and operating income
  • Reduced vehicle ASP due to mix shifts
  • Growth in Services and Other revenue up 17% YoY
  • Energy gross profit reached record $846 million
  • Increased R&D spending on AI and autonomy projects
  • Lower cost per vehicle from mix and lower raw materials, partially offset by lower fixed cost absorption and tariff increases
  • Decrease in restructuring charges improved operating expenses

Forward Guidance & Outlook

Tesla acknowledged difficulty measuring the impacts of shifting global trade and fiscal policies on cost structure and demand. The company stated it has sufficient liquidity to fund its product roadmap, long-term capacity expansion plans and other expenses, and will maintain a strong balance sheet during this uncertain period. Hardware-related profits are expected to be accompanied over time by an acceleration of AI, software and fleet-based profits. Tesla is focused on growing vehicle volumes in a capex-efficient manner using existing production capacity before building new lines. Plans for new vehicles launching in 2025 remain on track, including initial production of a more affordable model in H1 2025. Cybercab is scheduled for volume production starting in 2026 using an 'unboxed' manufacturing strategy. Semi is also slated for volume production in 2026.

TSLA YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$8.0B$16.0B$24.0B$25.5B$22.5BRevenue$4.6B$3.9BGross Profit$1.6B$923.0MOperating Income$1.4B$1.2BNet Income
$0$8.0B$16.0B$24.0BRevenueGross ProfitOperating IncomeNet Income

TSLA Revenue by Segment

Automotive Sales$15.8B
Automotive
Services and Other$3.0B+17.0%
Energy Generation and Storage$2.8B−7.0%
Automotive Regulatory Credits$439.0M
Automotive Leasing$435.0M

Figures from SEC filings and company reports. Not investment advice.